Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients

Powrózek, Tomasz; Krawczyk, Paweł; Nicoś, Marcin; Kuźnar-Kamińska, Barbara; Batura‐Gabryel, Halina; Milanowski, Janusz

doi:10.1007/s12094-015-1382-z

Cited by 51 publications

(41 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dclk1 promoter methylation was found in less then 10% of healthy individuals while almost 50% of the patients diagnosed with lung cancer had detectable levels of the methylated Dclk1 promoter in their plasma, and the methylation status was a predictor of poor survival in these patients. 54 Houchen and colleagues analyzed both circulating tumor cells and the serum of patients diagnosed with pancreatic cancer for Dclk1 expression. In a representative genetically engineered mouse model of pancreatic cancer, greater than 50% of all circulating tumor cells expressed Dclk1.…”

Section: Dclk1 As a Potential Tumor Markermentioning

confidence: 99%

Functional implication of Dclk1 and Dclk1-expressing cells in cancer

2016

View full text Add to dashboard Cite

Doublecortin like kinase protein 1 (Dclk1) is a microtubule-associated protein with C-terminal serine/threonine kinase domain. Originally designated Doublecortin and CaM kinase-like 1 protein (Dcamkl1) or KIAA0369, Dclk1 was first described as a marker for radial glia cells in the context of microtubule polymerization and neuronal migration, possibly contributing to early neurogenesis. Additionally, Dclk1 was proposed as a marker of quiescent gastrointestinal and pancreatic stem cells, but in recent years has been recognized as a marker for tuft cells in the gastrointestinal tract. While Dclk1C tuft cells are now considered as niche or sensory cells in the normal gut, growing evidence supports a role for Dclk1 function in a variety of malignancies, modulating the activity of multiple key pathways, including Kras signaling. Here, we review the recent advances in understanding of the importance of Dclk1 function in tumorigenesis and cancer.

show abstract

Section: Dclk1 As a Potential Tumor Markermentioning

confidence: 99%

Functional implication of Dclk1 and Dclk1-expressing cells in cancer

2016

View full text Add to dashboard Cite

show abstract

“…Also, a study by Wang et al found that increased APC and RASSF1A methylation levels in plasma cfDNA 24 hours post chemotherapy were correlated with a positive response to treatment in patients with advanced lung cancer [39]. In addition, in a study conducted to determine the methylation status of the DCLK1 promoter in plasma cfDNA from lung cancer patients across stages, 49.2% of plasma cfDNA samples were methylated [40]. Notably in this study, 73.7% and 39.1% of SCLC and NSCLC samples respectively exhibited DCLK1 plasma cfDNA methylation [40].…”

Section: Cell-free Dnamentioning

confidence: 99%

Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer

et al. 2016

View full text Add to dashboard Cite

Personalized medicine has emerged as the future of cancer care to ensure that patients receive individualized treatment specific to their needs. In order to provide such care, molecular techniques that enable oncologists to diagnose, treat, and monitor tumors are necessary. In the field of lung cancer, cell free DNA (cfDNA) shows great potential as a less invasive liquid biopsy technique, and next-generation sequencing (NGS) is a promising tool for analysis of tumor mutations. In this review, we outline the evolution of cfDNA and NGS and discuss the progress of using them in a clinical setting for patients with lung cancer. We also present an analysis of the role of cfDNA as a liquid biopsy technique and NGS as an analytical tool in studying EGFR and MET, two frequently mutated genes in lung cancer. Ultimately, we hope that using cfDNA and NGS for cancer diagnosis and treatment will become standard for patients with lung cancer and across the field of oncology.

show abstract

“…The authors have since patented hypermethylation of hDCLK1 gene promoter as a novel epigenetic biomarker for CRCs in patients. Since then, 5'promoter of hDCLK1 gene has been reported to be hypermethylated in gastric (38), pancreatic (38), and lung cancers (39). Interpretation of data in light of these important discoveries, has however remained ignored by some investigators, who have published since 2014 in this field (36,40).…”

mentioning

confidence: 99%

Epigenetic regulation of human DCLK-1 gene during colon-carcinogenesis: clinical and mechanistic implications

Singh

O’Connell

Sarkar

2016

Stem Cell Investig.

View full text Add to dashboard Cite

Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients

Abstract: The evaluation of DCLK1 promoter region methylation may be useful in both early diagnosis and prediction of the course of lung cancer.

Cited by 51 publications

References 20 publications

Functional implication of Dclk1 and Dclk1-expressing cells in cancer

Functional implication of Dclk1 and Dclk1-expressing cells in cancer

Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer

Epigenetic regulation of human DCLK-1 gene during colon-carcinogenesis: clinical and mechanistic implications

Contact Info

Product

Resources

About